TY  - JOUR
A1  - Brown, Nicholas M
A1  - Goodman, Anna L
A1  - Horner, Carolyne
A1  - Jenkins, Abi
A1  - Brown, Erwin M
JF  - JAC-Antimicrobial Resistance
PB  - OXFORD UNIV PRESS
UR  - https://doi.org/10.1093/jacamr/dlaa114
SN  - 2632-1823
N2  - These evidence-based guidelines are an updated version of those issued in 2008. They have beenproduced following a review of the published literature (2007-18) pertaining to the treatment of infections caused by MRSA. The guidelines update, where appropriate, previous recommendations, takinginto account changes in the UK epidemiology of MRSA, ongoing national surveillance data and the efficacy of novel anti-staphylococcal agents licensed for use in the UK. Emerging therapies that have not been licensed for use in the UK at the time of the review have also been assessed.
ID  - discovery10184149
IS  - 1
N1  - © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
VL  - 3
AV  - public
Y1  - 2021/03/01/
EP  - 18
TI  - Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK
ER  -